Irinotecan hydrochloride

盐酸伊立替康

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameIrinotecan hydrochloride
Drug Alias Name盐酸依立替康IrinotecanumIrnocam伊利替康盐酸盐Campotesin +[20] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCNS Embryonal TumorLiver DysfunctionSolid tumours +[81] 
Global Approved IndicationsLarge intestine neoplasmSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[13] 
Approved Indications in ChinaLarge intestine neoplasm
Original Approved Country/TerritoryJapan
Original Approved Date1994/01/19
Country/TerritoryBelgiumCanadaUnited States +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYakult Honsha Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIpsenUniversity Of California San FranciscoCRISM Therapeutics Ltd +[12] 
Inactive CompaniesKentuckiana Cancer InstituteLovelace Respiratory Research InstituteAugusta University +[29] 
Active IndicationsLarge intestine neoplasmSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[18] 
Inactive IndicationsCNS Embryonal TumorLiver DysfunctionSolid tumours +[63] 

Other Information

ATC CodeL01CE02
Related LinksWikipediaDrugBankKEGG